Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer.

Khanlari M, Schally AV, Block NL, Nadji M.

Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):1-5. doi: 10.1097/PAI.0000000000000622.

PMID:
29206714
2.

Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy.

Thounaojam MC, Powell FL, Patel S, Gutsaeva DR, Tawfik A, Smith SB, Nussbaum J, Block NL, Martin PM, Schally AV, Bartoli M.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13248-13253. doi: 10.1073/pnas.1718592114. Epub 2017 Nov 27.

3.

Expression of hypothalamic neurohormones and their receptors in the human eye.

Dubovy SR, Fernandez MP, Echegaray JJ, Block NL, Unoki N, Perez R, Vidaurre I, Lee RK, Nadji M, Schally AV.

Oncotarget. 2017 Jun 3;8(40):66796-66814. doi: 10.18632/oncotarget.18358. eCollection 2017 Sep 15.

4.

Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.

Schally AV, Block NL, Rick FG.

Prostate. 2017 Jun;77(9):1036-1054. doi: 10.1002/pros.23360. Epub 2017 Apr 27. Review.

PMID:
28449236
5.

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy.

Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC.

Urol Oncol. 2017 May;35(5):183-191. doi: 10.1016/j.urolonc.2017.01.025. Epub 2017 Mar 18. Review.

6.

Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro.

Köster F, Jin L, Shen Y, Schally AV, Cai RZ, Block NL, Hornung D, Marschner G, Rody A, Engel JB, Finas D.

Reprod Sci. 2017 Nov;24(11):1503-1511. doi: 10.1177/1933719117691140. Epub 2017 Feb 16.

PMID:
28205459
7.

Genitourinary sarcoidosis: An essential review for the practicing clinician.

Block NL, Kava BR.

Indian J Urol. 2017 Jan-Mar;33(1):6-12. doi: 10.4103/0970-1591.195724. Review.

8.

Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.

Zarandi M, Cai R, Kovacs M, Popovics P, Szalontay L, Cui T, Sha W, Jaszberenyi M, Varga J, Zhang X, Block NL, Rick FG, Halmos G, Schally AV.

Peptides. 2017 Mar;89:60-70. doi: 10.1016/j.peptides.2017.01.009. Epub 2017 Jan 24.

PMID:
28130121
9.

Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.

Gan J, Ke X, Jiang J, Dong H, Yao Z, Lin Y, Lin W, Wu X, Yan S, Zhuang Y, Chu WK, Cai R, Zhang X, Cheung HS, Block NL, Pang CP, Schally AV, Zhang H.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14745-14750. doi: 10.1073/pnas.1618582114. Epub 2016 Dec 7.

10.

Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.

Chu WK, Law KS, Chan SO, Yam JC, Chen LJ, Zhang H, Cheung HS, Block NL, Schally AV, Pang CP.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14396-14401. Epub 2016 Nov 23.

11.

Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.

Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV.

Oncotarget. 2016 Aug 16;7(33):52661-52672. doi: 10.18632/oncotarget.11024.

12.

Grade-dependent Response to Finasteride in Early Prostate Cancer.

Rick FG, Block NL.

EBioMedicine. 2016 May;7:13-4. doi: 10.1016/j.ebiom.2016.04.022. Epub 2016 Apr 19. No abstract available.

13.

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.

Ullrich M, Bergmann R, Peitzsch M, Zenker EF, Cartellieri M, Bachmann M, Ehrhart-Bornstein M, Block NL, Schally AV, Eisenhofer G, Bornstein SR, Pietzsch J, Ziegler CG.

Theranostics. 2016 Mar 10;6(5):650-65. doi: 10.7150/thno.14479. eCollection 2016.

14.

Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells.

Ma Q, Xia X, Tao Q, Lu K, Shen J, Xu Q, Hu X, Tang Y, Block NL, Webster KA, Schally AV, Wang J, Yu H.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):663-672. doi: 10.1161/ATVBAHA.116.307126. Epub 2016 Feb 11.

15.

Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Romero MJ, Lucas R, Dou H, Sridhar S, Czikora I, Mosieri EM, Rick FG, Block NL, Sridhar S, Fulton D, Weintraub NL, Bagi Z, Schally AV.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1895-900. doi: 10.1073/pnas.1525520113. Epub 2016 Feb 1.

16.

Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice.

Zhang X, Cui T, He J, Wang H, Cai R, Popovics P, Vidaurre I, Sha W, Schmid J, Ludwig B, Block NL, Bornstein SR, Schally AV.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13651-6. doi: 10.1073/pnas.1518540112. Epub 2015 Oct 16.

17.

Potential merger of ancient lineages in a passerine bird discovered based on evidence from host-specific ectoparasites.

Block NL, Goodman SM, Hackett SJ, Bates JM, Raherilalao MJ.

Ecol Evol. 2015 Sep;5(17):3743-55. doi: 10.1002/ece3.1639. Epub 2015 Aug 18.

18.

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

Schally AV, Block NL, Rick FG.

Asian J Androl. 2015 Nov-Dec;17(6):925-8. doi: 10.4103/1008-682X.152819.

19.

Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy.

Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, Golpanian S, Karantalis V, Wolf A, Wang B, Premer C, Balkan W, Rodriguez J, Valdes D, Rosado M, Block NL, Goldstein P, Morales A, Cai RZ, Sha W, Schally AV, Hare JM.

J Am Heart Assoc. 2015 Mar 31;4(4). pii: e001464. doi: 10.1161/JAHA.114.001464.

20.

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.

Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG.

Oncotarget. 2015;6(12):9728-39.

21.

Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.

Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, Glassberg MK, Block NL, Lew JI, Elliot SJ, Schally AV.

Horm Cancer. 2015 Jun;6(2-3):100-6. doi: 10.1007/s12672-015-0217-2. Epub 2015 Mar 10.

PMID:
25752763
22.

Transplantation of bovine adrenocortical cells encapsulated in alginate.

Balyura M, Gelfgat E, Ehrhart-Bornstein M, Ludwig B, Gendler Z, Barkai U, Zimerman B, Rotem A, Block NL, Schally AV, Bornstein SR.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2527-32. doi: 10.1073/pnas.1500242112. Epub 2015 Feb 9.

23.

Potentiating effects of GHRH analogs on the response to chemotherapy.

Schally AV, Perez R, Block NL, Rick FG.

Cell Cycle. 2015;14(5):699-704. doi: 10.1080/15384101.2015.1010893.

24.

Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation.

Qin YJ, Chan SO, Chong KK, Li BF, Ng TK, Yip YW, Chen H, Zhang M, Block NL, Cheung HS, Schally AV, Pang CP.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18303-8. doi: 10.1073/pnas.1421815112. Epub 2014 Dec 8.

25.

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG.

Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879.

26.

Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.

Florea V, Majid SS, Kanashiro-Takeuchi RM, Cai RZ, Block NL, Schally AV, Hare JM, Rodrigues CO.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17260-5. doi: 10.1073/pnas.1420375111. Epub 2014 Nov 17.

27.

In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma.

Ullrich M, Bergmann R, Peitzsch M, Cartellieri M, Qin N, Ehrhart-Bornstein M, Block NL, Schally AV, Pietzsch J, Eisenhofer G, Bornstein SR, Ziegler CG.

Endocrinology. 2014 Nov;155(11):4149-56. doi: 10.1210/en.2014-1431. Epub 2014 Aug 19.

28.

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction.

Czikora I, Sridhar S, Gorshkov B, Alieva IB, Kasa A, Gonzales J, Potapenko O, Umapathy NS, Pillich H, Rick FG, Block NL, Verin AD, Chakraborty T, Matthay MA, Schally AV, Lucas R.

Front Physiol. 2014 Jul 15;5:259. doi: 10.3389/fphys.2014.00259. eCollection 2014.

30.

Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.

Mezey G, Treszl A, Schally AV, Block NL, Vízkeleti L, Juhász A, Klekner A, Nagy J, Balázs M, Halmos G, Bognár L.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1641-9. doi: 10.1007/s00432-014-1716-1. Epub 2014 Jun 1.

PMID:
24878932
31.

Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV.

World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102. Review.

32.

Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.

Ludwig B, Barthel A, Reichel A, Block NL, Ludwig S, Schally AV, Bornstein SR.

Vitam Horm. 2014;95:195-222. doi: 10.1016/B978-0-12-800174-5.00008-9. Review.

PMID:
24559919
33.

Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance.

Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, van den Berg S, Soehnlein O, Winkels H, Beckers L, Lievens D, Driessen A, Kusters P, Biessen E, Garcia-Martin R, Klotzsche-von Ameln A, Gijbels M, Noelle R, Boon L, Hackeng T, Schulte KM, Xu A, Vriend G, Nabuurs S, Chung KJ, Willems van Dijk K, Rensen PC, Gerdes N, de Winther M, Block NL, Schally AV, Weber C, Bornstein SR, Nicolaes G, Chavakis T, Lutgens E.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2686-91. doi: 10.1073/pnas.1400419111. Epub 2014 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4644. Schulte, Klaus [corrected to Schulte, Klaus-Martin].

34.

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.

Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.

35.

Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists.

Jaszberenyi M, Rick FG, Popovics P, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Schally AV.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):781-6. doi: 10.1073/pnas.1322622111. Epub 2013 Dec 30.

36.

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.

Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, Popovics P, Kanashiro-Takeuchi R, Hare JM, Block NL, Zarandi M.

Peptides. 2014 Feb;52:104-12. doi: 10.1016/j.peptides.2013.12.010. Epub 2013 Dec 25.

37.

Transplantation of human islets without immunosuppression.

Ludwig B, Reichel A, Steffen A, Zimerman B, Schally AV, Block NL, Colton CK, Ludwig S, Kersting S, Bonifacio E, Solimena M, Gendler Z, Rotem A, Barkai U, Bornstein SR.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19054-8. doi: 10.1073/pnas.1317561110. Epub 2013 Oct 28.

38.

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.

Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, Rozsa B, Fodor K, Buglyo A, Gardi J, Berta A, Halmos G.

Oncotarget. 2013 Oct;4(10):1721-8.

39.

Agonists of luteinizing hormone-releasing hormone in prostate cancer.

Rick FG, Block NL, Schally AV.

Expert Opin Pharmacother. 2013 Nov;14(16):2237-47. doi: 10.1517/14656566.2013.834328. Epub 2013 Aug 28. Review.

PMID:
23984804
40.

Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation.

Kanczkowski W, Alexaki VI, Tran N, Großklaus S, Zacharowski K, Martinez A, Popovics P, Block NL, Chavakis T, Schally AV, Bornstein SR.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14801-6. doi: 10.1073/pnas.1313945110. Epub 2013 Aug 19.

41.

Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs.

Lucas R, Czikora I, Sridhar S, Zemskov E, Gorshkov B, Siddaramappa U, Oseghale A, Lawson J, Verin A, Rick FG, Block NL, Pillich H, Romero M, Leustik M, Schally AV, Chakraborty T.

Toxins (Basel). 2013 Jul 15;5(7):1244-60. doi: 10.3390/toxins5071244. Review.

42.

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

43.

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

Rick FG, Block NL, Schally AV.

Onco Targets Ther. 2013 Apr 16;6:391-402. doi: 10.2147/OTT.S32426. Print 2013.

44.

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

45.

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.

Jaszberenyi M, Schally AV, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Rick FG.

Target Oncol. 2013 Dec;8(4):281-90. doi: 10.1007/s11523-013-0264-y. Epub 2013 Feb 1.

PMID:
23371031
46.

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, Krishan A, Block NL, Schally AV.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2617-22. doi: 10.1073/pnas.1222355110. Epub 2013 Jan 28.

47.

Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone.

Schubert U, Schmid J, Lehmann S, Zhang XY, Morawietz H, Block NL, Kanczkowski W, Schally AV, Bornstein SR, Ludwig B.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2288-93. doi: 10.1073/pnas.1221505110. Epub 2013 Jan 23.

48.

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.

Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.

Prostate. 2013 Jun;73(8):873-83. doi: 10.1002/pros.22633. Epub 2012 Dec 31.

PMID:
23280565
49.

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease.

Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV.

Aging (Albany NY). 2012 Nov;4(11):755-67.

50.

Hormonal manipulation of benign prostatic hyperplasia.

Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B, Schally AV.

Curr Opin Urol. 2013 Jan;23(1):17-24. doi: 10.1097/MOU.0b013e32835abd18. Review.

PMID:
23202285

Supplemental Content

Loading ...
Support Center